An observational study in Bronchiectasis, sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Recruiting at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-05.
Sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Observational
Among 84 studies in Bronchiectasis with a site in China — 35 open to participants now, 38 under way, 4 of them phase 3. Bronchiectasis · China.
Among the 84 studies in Bronchiectasis with a site in China, this one is the 30th largest by planned enrollment of the 34 observational ones that give a count, is one of 6 that started in 2021, is one of 34 observational ones, reaches primary completion later than 36 of the 37 other live ones, and was the 37th registered.
404 studies on the registry are indexed under Bronchiectasis; 125 are open to participants now.
Browse Bronchiectasis studies →35 of the 84 studies in Bronchiectasis with a site in China are open now. Recruiting first, the newest first:
Haisco Pharmaceutical Group Co., Ltd. · Sites in China
Shanghai Pulmonary Hospital, Shanghai, China · Sites in China
AstraZeneca · Sites in China
Haisco Pharmaceutical Group Co., Ltd. · Sites in China
First Affiliated Hospital of Ningbo University · Sites in China
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 93 Bronchiectasis studies recruiting now, 50 (54%) set no upper age limit and 13 (14%) stop at 75 or younger; 12 take children under 18; 26 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 12 · Phase 3 7 · Phase 4 14
First in 2011; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is close to the median of 160 across 137 observational studies indexed under Bronchiectasis.
Median enrollment 120 across the 50 interventional studies, 300 across the 34 observational. Of the 23 that completed or were terminated, 8 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 84 have an industry lead sponsor. The 10 most frequent:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology is the lead sponsor of 181 studies on the registry; 144 are open to participants now.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology has 4 studies filed under Bronchiectasis — fewer than ten, so there is no comparison to draw.
15 of the studies in Bronchiectasis with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06660992Phase 3Haisco Pharmaceutical Group Co., Ltd.A Study to Assess the Efficacy and Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis | 2026-11-28 |
| NCT06872892Phase 3Boehringer IngelheimThe AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis | 2027-06-15 |
| NCT07915024Haisco Pharmaceutical Group Co., Ltd.Phase 1 Study to Assess the Effects of HSK31858 on the QT/QTc Interval in Healthy Chinese Participants | 2026-11 |
| NCT07915011Haisco Pharmaceutical Group Co., Ltd.Investigation of Pharmacokinetics, Safety of HSK31858 in Subjects With Renal Impairment | 2026-11 |
| NCT07913009Haisco Pharmaceutical Group Co., Ltd.Investigation of Pharmacokinetics, Safety of HSK31858 in Subjects With Hepatic Impairment | 2026-12 |
Among the 84 studies in Bronchiectasis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Bronchiectasis is a chronic inflammatory respiratory disease defined as the irreversible dilatation of one or more bronchi and is associated with chronic and frequently purulent expectoration, multiple exacerbations and progressive dyspnea. Bronchiectasis has a large heterogeneity. Different patients with bronchiectasis may have different etiology, clinical manifestations, and imaging features. Previous studies showed that there are significant relationship between the airway microbiome and the severity of the disease. For example, patient with airway Pseudomonas aeruginosa colonization has heavier symptoms, heavier severity, poorer quality of life, more acute exacerbations, and worse prognosis. A large number of studies have reported that long-term treatment of low-dose macrolides such as azithromycin or clarithromycin has anti-inflammatory and immunomodulatory effects, which can improve the clinical symptoms and disease progression of various chronic airway diseases, such as diffuse panbronchiolitis, chronic obstructive pulmonary disease, bronchiectasis. Both the 2017 European Respiratory Society guidelines and the 2019 British Thoracic Society Guideline recommend macrolide drugs for the treatment of chronic Pseudomonas aeruginosa colonization bronchiectasis or frequent acute exacerbations bronchiectasis, but the specific mechanism is unknown.This study is based on omics methods (Microbiology and Metabolomics) to deeply explore the composition of airway and gut microbiota in patients with bronchiectasis, the factors affecting the colonization of Pseudomonas aeruginosa and the mechanism of macrolides in the treatment of bronchiectasis.
This project is a multicenter clinical study involving patients with bronchiectasis from Wuhan Union Hospital, Guizhou Provincial People's Hospital, and Yichang Central People's Hospital. Patients with bronchiectasis were recruited according to the inclusion and exclusion criteria. Clinical data were collected from these patients (including demographic information, clinical characteristics, pulmonary function, and lung imaging), along with spontaneously expectorated sputum, feces, and peripheral blood, and the patients were followed for 24 months. The microbiome, metabolome, and cytokines in sputum and feces were assessed, as well as cytokines, inflammatory mediators, and metabolites in peripheral blood.
Through the above methods,investigators further understand the mechanism affecting progression of bronchiectasis and some factors that lead to the colonization of Pseudomonas aeruginosa, as well as mechanisms of macrolides in the treatment of bronchiectasis.
Clinical information:
Demographic information,blood test results,lung function,severity of disease was evaluated using the E-FACED and the Bronchiectasis Severity Index (BSI).The severity of dyspnea was assessed using the Medical Research Council (MRC) grade, and lung radiological severity was assessed using the modified Reiff score and Bhalla score.
Sputum collection:
We collect sputum samples from patients with bronchiectasis. We divided into two parts from each sputum sample, one part was immediately stored -80℃ for microbiota sequencing. The other part was diluted with PBS and centrifuged at 12000g for 5 minutes, and the supernatant was stored at -80°C for measurement of inflammatory factors, oxidative stress and other markers.
Stool collection:
We collect stool samples from patients with bronchiectasis.Fresh stools were processed in the laboratory within 30 min after collection and stored at -80°C until analysis.
Peripheral blood collection:
We collect peripheral blood samples from patients with bronchiectasis to detect inflammatory mediators and so on.
All patients with bronchiectasis was recruited from Wuhan Union Hospital.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Colonization of Pseudomonas aeruginosa in the airways of patients with bronchiectasis
Diagnostic Test: Pseudomonas aeruginosa colonization infection
No colonization of Pseudomonas aeruginosa in the airways of patients with bronchiectasis
Diagnostic Test: Pseudomonas aeruginosa colonization infection
Before treatment with macrolides in patients with bronchiectasis
Drug: Macrolides
After 6 months of treatment with macrolides for patients with bronchiectasis
Drug: Macrolides
With or without airway Pseudomonas aeruginosa colonization infection
Before or after 6 months of treatment with macrolides for patients with bronchiectasis
Acute exacerbations and mortality
The number of acute exacerbations and outcome (death or survival) of patients with bronchiectasis after one year.
Time frame: February 10, 2026
Lung function
Forced expiratory volume in 1s (FEV1),Forced vital capacity（FVC）
Time frame: February 10, 2026
Symptoms assessment
MRC score,cough score,sputum purulent score,sputum volume score and hemoptysis score
Time frame: February 10, 2026
Stool and sputum microtioba
Stool and sputum microtioba from patients with bronchiectasis after one year
Time frame: February 10, 2026
Plan to share: Undecided
Started Feb 2021 (actual). Primary completion is estimated for Dec 2030, 118 months after the start.
Of 62 observational studies under Bronchiectasis, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 12. This study's planned 118 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology →